Bendtsen P, Akerlind I, Hörnquist J O
Department of Community Medicine, University of Linköping, Sweden.
Drugs Aging. 1995 Nov;7(5):338-46. doi: 10.2165/00002512-199507050-00002.
Despite the rather pessimistic outlook regarding the long term effects of pharmacological treatment of patients with rheumatoid arthritis (RA), there is no doubt that drug interventions can affect quality of life (QOL). The disease has a significant impact upon physical, psychological and social function, and QOL optimisation should cover all these dimensions. Swelling of joints and pain are important manifestations in assessing RA since these may result in sleep disturbances as well as depressed mood. This might be particularly significant for older persons with RA. Outcome parameters of RA can be divided into short, intermediate and long term. The long term results are quite disappointing with regard to disability and premature death. However, more intermediate outcome measures related to QOL might improve after pharmacological interventions. Patient preferences and expectations with regard to the outcome of pharmacological interventions are important parameters to assess. When assessing older patients with RA with QOL instruments, it is recommended that questionnaires are fairly short and easy to complete. Adverse effects of pharmacological interventions are important factors to monitor in QOL assessment in older patients with reduced remaining life span.
尽管对于类风湿关节炎(RA)患者药物治疗的长期效果看法颇为悲观,但药物干预无疑会影响生活质量(QOL)。该疾病对身体、心理和社会功能有重大影响,优化生活质量应涵盖所有这些方面。关节肿胀和疼痛是评估类风湿关节炎的重要表现,因为这些可能导致睡眠障碍以及情绪低落。这对于老年类风湿关节炎患者可能尤为重要。类风湿关节炎的结果参数可分为短期、中期和长期。就残疾和过早死亡而言,长期结果相当令人失望。然而,与生活质量相关的更多中期结果指标在药物干预后可能会有所改善。患者对药物干预结果的偏好和期望是重要的评估参数。在用生活质量工具评估老年类风湿关节炎患者时,建议问卷相当简短且易于填写。在评估剩余寿命缩短的老年患者的生活质量时,药物干预的不良反应是需要监测的重要因素。